Andrew Bab, M&A partner at Debevoise & Plimpton LLP, is advising J.P. Morgan Securities LLC as financial advisor to PPD Inc., (NASDAQ: PPD) in its sale to Thermo Fisher (NYSE: TMO) for $17.4 billion in cash plus $3.5 billion of net debt. For more information, please see the company’s press release.

PPD is a leading global contract research organization providing comprehensive, integrated drug development, laboratory and lifecycle management services. Thermo Fisher is a leader in serving science, with annual revenue exceeding $30 billion, and delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through its industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services and Patheon.